Quick Answer
BeOne Medicines Ltd. reported Operating Income Loss of $447.14 million for the year ending 2025.
- BeOne Medicines Ltd. showed an increase of +178.7% in Operating Income Loss from 2024 to 2025.
- This data is from BeOne Medicines Ltd.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$9.81 million | Q2 2015: -$6.57 million | Q3 2015: -$13.99 million | Q4 2015: -$26.38 million | Q1 2016: -$20.33 million | Q2 2016: -$24.63 million | Q3 2016: -$34.83 million | Q4 2016: -$37.27 million | Q1 2017: -$51.54 million | Q2 2017: -$58.02 million | Q3 2017: $114.91 million | Q4 2017: -$103.80 million | Q1 2018: -$110.81 million | Q2 2018: -$163.05 million | Q3 2018: -$151.10 million | Q4 2018: -$280.81 million | Q1 2019: -$173.76 million | Q2 2019: -$85.83 million | Q3 2019: -$312.27 million | Q4 2019: -$388.04 million | Q1 2020: -$373.76 million | Q2 2020: -$358.88 million | Q3 2020: -$440.14 million | Q4 2020: -$484.91 million | Q1 2021: $70.17 million | Q2 2021: -$474.84 million | Q3 2021: -$462.33 million | Q1 2022: -$443.29 million | Q2 2022: -$439.40 million | Q3 2022: -$438.36 million | Q1 2023: -$371.26 million | Q2 2023: -$318.72 million | Q3 2023: -$133.97 million | Q1 2024: -$261.35 million | Q2 2024: -$107.16 million | Q3 2024: -$120.27 million | Q1 2025: $11.10 million | Q2 2025: $87.89 million | Q3 2025: $163.11 million.
- Over the full 12 years of available data (2014 to 2025), BeOne Medicines Ltd.'s Operating Income Loss has grown by 2,937.7%.
- Historical annual values: Fiscal year 2025: $447.14 million | Fiscal year 2024: -$568.20 million | Fiscal year 2023: -$1.21 billion | Fiscal year 2022: -$1.79 billion | Fiscal year 2021: -$1.44 billion | Fiscal year 2020: -$1.66 billion | Fiscal year 2019: -$959.89 million | Fiscal year 2018: -$705.77 million | Fiscal year 2017: -$98.46 million | Fiscal year 2016: -$117.06 million | Fiscal year 2015: -$56.75 million | Fiscal year 2014: -$15.76 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: